Plavix Could Face Rival Prasugrel In Second Half
This article was originally published in PharmAsia News
Executive Summary
Lilly and Daiichi Sankyo will launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force that includes representatives from both companies, Lilly's head of cardiovascular research, J. Anthony Ware, told "The Pink Sheet" DAILY